알파-1폐질환 시장 : 질환 유형별, 치료 유형별, 투여 경로별, 유통 채널별, 지역별
Alpha 1 Lung Disease Market, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Region
상품코드
:
1741400
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
알파-1폐질환 시장은 2025년 70억 5,000만 달러, 2032년에는 236억 8,000만 달러에 이르고, 2025-2032년 연평균 복합 성장률(CAGR) 18.9%의 성장이 예측됩니다.
| 보고서 범위 |
보고서 상세 |
| 기준 연도 |
2024 |
2025년 시장 규모 |
70억 5,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간(2025-2032년) CAGR |
18.90% |
2032년 가치 예측 |
236억 8,000만 달러 |
알파-1 폐질환은 폐와 간을 침범하는 희귀한 유전성 질환입니다. 폐를 손상으로부터 보호하는 단백질인 알파-1 항트립신(AAT)의 결핍이 원인입니다. 이 질환은 만성폐쇄성폐질환(COPD)과 간질환의 발병으로 이어집니다.
세계 알파-1 폐질환 시장은 유병률 증가, 의료 전문가들의 인식 증가, 진단 기술 발전에 힘입어 성장하고 있습니다. 알파-1 재단에 따르면 미국과 유럽에서 약 10만 명이 알파-1 폐질환을 앓고 있는 것으로 추정됩니다. 그러나 실제 환자 수는 이보다 훨씬 더 많을 것으로 추정됩니다.
시장 역학:
알파-1 폐질환 시장은 주로 유병률 증가에 의해 주도되고 있습니다. 알파-1 폐질환 진단을 받는 환자가 증가함에 따라 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 이에 따라 시장의 주요 업체들의 연구개발 활동이 활발해지고 있습니다.
그러나 시장 성장을 저해하는 요인도 있습니다. 일반인 및 의료 전문가들 사이에서 이 질병에 대한 인식이 낮기 때문에 조기 진단 및 조기 치료에 걸림돌이 되고 있습니다. 또한, 일부 지역에서는 높은 치료 비용과 상환 정책의 부재가 시장 성장의 걸림돌로 작용하고 있습니다.
이러한 과제에도 불구하고, 시장에는 몇 가지 성장 기회가 있습니다. 유전자 검사 등 진단 기술의 발전으로 조기 발견율이 향상될 것으로 예측됩니다. 또한, 새로운 치료제와 표적 치료제의 개발은 알파-1 폐질환의 치료에 유망합니다.
예를 들어, 2022년 6월 미국 식품의약국(FDA) 의약품평가연구센터(CDER)와 생물학적제제평가연구센터(CBER)는 미국 내 센터인 미국 식품의약국(FDA) 의약품평가연구센터(CDER)와 생물학적제제평가연구센터(CBER)가 비 비영리 단체인 중요 경로 연구소(C-Path)와 제휴하여 조기 사망 및 폐 이식을 필요로 하는 희귀질환인 알파-1 항트립신 결핍증(AATD)에 대한 임상 개발 프로그램에 사용할 수 있는 도구를 개발하기 위해 컨소시엄 계획을 시작한다고 발표합니다.
본 조사의 주요 특징
- 본 보고서는 알파-1 폐질환 세계 시장을 상세하게 분석했으며, 시장 규모와 2025-2032년 예측 기간의 CAGR 등의 정보를 정리하여 전해드립니다.
- 이 보고서는 다양한 부문의 잠재적 수익 성장 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 주요 기업으로는 AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc. Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc. Gilead Sciences, Inc., AbbVie Inc., Regeneron Pharmaceuticals Inc. 등이 있습니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 알파-1 폐 질환 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 알파-1 폐질환 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COaM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 발매 및 승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
제4장 알파-1폐질환 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측 분석
- 경제에 대한 영향
제5장 알파-1폐질환 시장, 질환 유형별, 2020년-2032년
- 알파-1 항트립신 결핍증
- 만성 폐쇄성 폐질환(COPD)
- 폐 섬유증
- 기관지 확장증
- 기타
제6장 알파-1폐질환 시장, 치료 유형별, 2020년-2032년
- 증강 요법
- 기관지 확장제
- 코르티코스테로이드
- 산소 요법
- 폐이식
- 기타
제7장 알파-1폐질환 시장, 투여 경로별, 2020-2032년
제8장 알파-1폐질환 시장, 유통 채널별, 2020년-2032년
제9장 알파-1폐질환 시장, 지역별, 2020년-2032년
- 북미
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제10장 경쟁 구도
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company Limited.
- CSL Behring
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Sanofi
- GSK plc
- Gilead Sciences, Inc.
- AbbVie Inc.
- Regeneron Pharmaceuticals Inc.
제11장 섹션
LSH
영문 목차
Alpha 1 Lung Disease Market is estimated to be valued at USD 7.05 Bn in 2025 and is expected to reach USD 23.68 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.9% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 7.05 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
18.90% |
2032 Value Projection: |
USD 23.68 Bn |
Alpha 1 Lung Disease is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency of alpha-1 antitrypsin (AAT), a protein that helps protect the lungs from damage. This condition leads to the development of chronic obstructive pulmonary disease (COPD) and liver disease.
The global Alpha 1 Lung Disease market is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the U.S. and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.
Market Dynamics:
The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.
However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.
Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.
For instance, in June 2022, U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the Center within the U.S. Food and Drug Administration (FDA) are pleased to announce their partnership with the Critical Path Institute (C-Path), a non-profit organization to initiate planning for a consortium aimed at developing tools appropriate for use in clinical development programs for alpha-1 antitrypsin deficiency (AATD), a rare disease causing progressive destruction of lung tissue leading to premature mortality or need for lung transplant.
Key Features of the Study:
- This report provides an in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period 2025-2032
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- The key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc., Sanofi, GSK plc, Gilead Sciences, Inc., AbbVie Inc., and Regeneron Pharmaceuticals Inc.
- Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
- The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market
Alpha 1 Lung Disease Market Segmentation:
- By Disease Type
- Alpha-1 Antitrypsin Deficiency
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Bronchiectasis
- Others
- By Treatment Type
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Lung Transplantation
- Others
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F.Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.,
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company Limited.
- CSL Behring
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Sanofi
- GSK plc
- Gilead Sciences, Inc.
- AbbVie Inc.
- Regeneron Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Alpha 1 Lung Disease, By Disease Type
- Market Alpha 1 Lung Disease, By Treatment Type
- Market Alpha 1 Lung Disease, By Route of Administration
- Market Alpha 1 Lung Disease, By Distribution Channel
- Market Alpha 1 Lung Disease, By Region
- Coherent Opportunity Map (COaM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising Prevalence of COPD Globally
- Increasing Diagnosis Rates
- New Product Launches
- Strong Pipeline of Drugs
- Limited awareness about the disease among the general population
- Technological advancements in diagnostic techniques
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Alpha 1 Lung Disease Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Alpha 1 Lung Disease Market, By Disease Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Alpha-1 Antitrypsin Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Pulmonary Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Bronchiectasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Alpha 1 Lung Disease Market, By Treatment Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Augmentation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Oxygen Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Lung Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
7. Alpha 1 Lung Disease Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
8. Alpha 1 Lung Disease Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
9. Alpha 1 Lung Disease Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
관련자료
